Zepbound Eligibility: Understanding Who Shouldn’t Take Tirzepatide for Weight Loss

Last reviewed: June 6, 2026

Last updated: June 6, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Tirzepatide represents a dual-action GLP-1 and GIP receptor agonist that has transformed weight management outcomes for millions of patients. However, certain medical conditions, medication interactions, and personal circumstances mean tirzepatide is not the right choice for everyone seeking weight loss treatment.

Medical Conditions That Contraindicate Tirzepatide Use

Personal or family history of medullary thyroid carcinoma (MTC) represents the most serious absolute contraindication to tirzepatide therapy. Preclinical animal studies demonstrated dose-dependent thyroid C-cell tumors with GLP-1 receptor agonists, and this risk remains unquantified in human populations. Patients with a prior diagnosis of MTC or multiple endocrine neoplasia syndrome type 2 (MEN2) must explore alternative weight loss strategies with their physician.

Severe pancreatitis history, whether acute or chronic, warrants careful consideration before starting tirzepatide. While GLP-1 medications do not directly cause pancreatitis in most patients, individuals with previous episodes face elevated baseline risk, and tirzepatide-induced rapid gastric emptying changes may trigger recurrence. Your medical team should evaluate the benefit-risk ratio in these cases.

Diabetic retinopathy—particularly proliferative forms—requires specialist oversight before tirzepatide initiation. Rapid blood sugar drops can temporarily worsen vision complications in patients with existing eye disease, though this risk is manageable under close ophthalmologic monitoring. Patients with stable, non-proliferative retinopathy often tolerate tirzepatide safely when doses escalate gradually.

Medication Interactions and Combination Therapy Concerns

Concurrent use of other GLP-1 receptor agonists, SGLT2 inhibitors, or dipeptidyl peptidase-4 (DPP-4) inhibitors requires physician coordination due to overlapping mechanisms and hypoglycemia risk. Tirzepatide amplifies insulin sensitivity and glucose control, and stacking multiple agents targeting the same pathways can precipitate dangerous blood sugar drops, particularly in patients already using insulin. PlexusDx recommends reviewing your complete medication list with a prescribing provider before starting treatment.

Certain gastroparesis medications and prokinetic agents may counteract tirzepatide's appetite-suppressing effects by opposing gastric slowdown. Additionally, medications that reduce gastrointestinal motility—such as opioids or anticholinergics—compound tirzepatide's naturally slowing effect on stomach emptying, raising nausea and vomiting risk. Patients taking these classes should discuss timing, dose adjustments, or alternative therapies with their healthcare provider.

Pregnancy, Breastfeeding, and Fertility Considerations

Tirzepatide has not been adequately studied in pregnant patients and is generally contraindicated during pregnancy and the postpartum breastfeeding period. Animal reproduction studies showed fetal toxicity at high doses, and sufficient human safety data do not yet exist to recommend routine use in expectant mothers. Women of childbearing potential should use reliable contraception during tirzepatide therapy and pause treatment if pregnancy is planned.

The impact of tirzepatide on milk supply and infant safety through breast milk remains unknown. Lactating mothers seeking weight loss should postpone tirzepatide therapy or consult lactation specialists and obstetricians to weigh risks against benefits. For patients focused on postpartum weight management, delaying treatment until breastfeeding is complete offers the safest pathway.

Personal History of Thyroid Disease and Monitoring Requirements

Patients with pre-existing thyroid nodules, thyroiditis, or autoimmune thyroid conditions (such as Hashimoto's disease) require baseline and periodic monitoring during tirzepatide therapy. While GLP-1 medications do not directly cause thyroid cancer in humans, the preclinical animal signal means individuals with underlying thyroid vulnerability deserve heightened surveillance. Regular thyroid ultrasounds and TSH checks help detect any nodule growth or functional changes early.

Hypothyroidism or hyperthyroidism management may become more complex once tirzepatide begins, as weight loss itself shifts thyroid hormone requirements and dosing needs. Patients on levothyroxine or other thyroid replacement should coordinate with their endocrinologist to adjust thyroid medication timing and doses in response to weight changes and tirzepatide introduction. PlexusDx supports coordinated care between your weight loss provider and thyroid specialist to optimize outcomes.

When Genetic Testing Helps Guide Your Tirzepatide Decision

PlexusDx's Precision Peptide Genetic Test examines genetic variants across 14 peptide pathways—including GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313)—to reveal your body's natural responsiveness to tirzepatide before starting treatment. Patients carrying loss-of-function variants in GLP1R may experience diminished appetite suppression, while those with GIPR variants may respond preferentially to semaglutide or combination therapy instead. Understanding your genetic predisposition empowers you to choose the therapy most likely to succeed for your biology.

The Precision Peptide Genetic Test costs $99 as an add-on after your first month of treatment with PlexusDx, allowing you to confirm tirzepatide is working as expected or pivot to oral semaglutide, compounded semaglutide injection, or the GLP-Squared dual-compound formula if your results suggest suboptimal response. This personalized approach removes guesswork and aligns your medication with your unique peptide physiology.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can I take tirzepatide if I have a history of thyroid cancer in my family?

No. If you or a close relative have been diagnosed with medullary thyroid carcinoma or MEN2 syndrome, tirzepatide is absolutely contraindicated and you should not start treatment. Alternative weight loss medications and lifestyle approaches exist and should be discussed with an oncologist or endocrinologist. PlexusDx can help you explore other GLP-1 options if your risk profile allows.

Is tirzepatide safe if I'm taking insulin for type 2 diabetes?

Tirzepatide can be combined with insulin, but it requires careful monitoring and dose adjustments because both medications lower blood sugar. Your prescriber must reduce your insulin doses gradually as you begin tirzepatide to prevent dangerous hypoglycemia. Frequent blood glucose checks and close communication with your care team are essential during this transition.

What does PlexusDx's Precision Peptide Genetic Test tell me about my tirzepatide response?

The test analyzes 150+ genetic insights across 49 peptides to show whether your GLP1R, GIPR, FTO, and MC4R genes predict strong, moderate, or weak tirzepatide response. If results suggest poor GLP1R function, you may respond better to semaglutide or our GLP-Squared dual formula. At $99, this add-on test performed after month one helps you optimize therapy before investing further time.

Can I use tirzepatide while breastfeeding?

No. Tirzepatide's safety in breastfed infants is unknown, and it is not recommended during lactation. If you are nursing and seeking weight loss, discuss alternatives with your OB-GYN or discuss pausing breastfeeding if tirzepatide is medically urgent. Most patients successfully delay treatment until after weaning.

How much does compounded tirzepatide injection cost at PlexusDx?

PlexusDx's Compounded Tirzepatide Injection starts at $249 per month flat across all commitment tiers—your dose may need to go up, but your price won't. All medications come from licensed 503A compounding pharmacies, require no insurance, and are HSA/FSA eligible. PlexusDx serves all 50 states with no membership fees.

Related Reading

• Tirzepatide For Weight Loss 2
• Wegovy Vs Zepbound Weight Loss
• Zepbound For Weight Loss
• Tirzepatide Vs Semaglutide For Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.